Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Invivyd (Nasdaq: IVVD) announced inducement option grants made April 1, 2026, to 16 newly hired non-executive employees totaling 1,083,750 options under the Invivyd 2026 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The options carry a per-share exercise price of $1.33 (closing price on the grant date), vest over four years with 25% after one year and monthly vesting thereafter, and have a 10-year term, subject to plan terms and continuous service.

Positive

• 1,083,750 options granted to 16 new hires
• Exercise price set at $1.33, equal to closing price on grant date
• Standard 4-year vesting with 25% after year one

Negative

• Potential dilution of 1,083,750 shares if options are exercised
• 10-year option term creates extended potential share overhang

News Market Reaction – IVVD

+1.56%

10 alerts

+1.56% Session close to close

-11.8% Trough in 25 hr 47 min

$367.37M Market Cap

0.2x Rel. Volume

In the Apr 6 session, IVVD gained 1.56%, reflecting a mild positive market reaction. Argus tracked a trough of -11.8% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details inducement stock options covering 1,083,750 shares for 16 new non-executiv...

Analysis

This announcement details inducement stock options covering 1,083,750 shares for 16 new non-executive employees, granted under Nasdaq Listing Rule 5635(c)(4) at an exercise price of $1.33 and vesting over 4 years with a 10-year term. It follows similar inducement grants disclosed in March. In context, Invivyd already maintains an active Form S-3 shelf and has used it via 424B5 offerings, so investors may continue to monitor overall equity issuance and insider activity when assessing dilution risk.

Key Figures

New hires covered: 16 employees Inducement option pool: 1,083,750 shares Option exercise price: $1.33 per share +4 more

7 metrics

New hires covered 16 employees Non-executive employees receiving inducement stock options

Inducement option pool 1,083,750 shares Aggregate common shares underlying inducement options granted Apr 1, 2026

Option exercise price $1.33 per share Exercise price equal to IVVD closing price on grant date

Initial vesting cliff 25% after 1 year Portion of each option vesting on first employment anniversary

Vesting period 4 years Options vest over four years with monthly vesting after year one

Option term 10 years Expiration period for inducement stock options

Grant date April 1, 2026 Date inducement stock options were granted

Historical Context

5 past events · Latest: Mar 30 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 30	Conference presentation	Positive	+9.2%	CSO presented Invivyd’s monoclonal antibody strategy at World Vaccine Congress.
Mar 05	Earnings & trial update	Positive	+1.8%	Reported 2025 results, PEMGARDA revenue growth, and DECLARATION Phase 3 progress.
Mar 05	Executive appointment	Positive	+1.8%	Appointed Michael Mina, M.D., Ph.D., as Chief Medical Officer.
Mar 02	Earnings call notice	Neutral	-5.8%	Scheduled Q4 and full-year 2025 financial results conference call.
Mar 02	Inducement option grants	Neutral	-5.8%	Granted 192,000 inducement stock options to new non-executive employees.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive corporate and clinical updates have generally seen aligned positive price reactions, while neutral items like inducement grants or call announcements have coincided with downside.

Recent Company History

Over the last few months, Invivyd has highlighted several milestones. On Mar 5, 2026, it reported 2025 financials and DECLARATION trial progress, with PEMGARDA revenue of $53.4M for 2025 and cash of $226.7M, and the stock rose modestly. Leadership was strengthened with a new Chief Medical Officer on Mar 5, and a scientific presentation at the World Vaccine Congress on Mar 30 also saw a positive reaction. By contrast, routine items like conference-call notices and prior inducement option grants on Mar 2 aligned with share price pressure.

Key Terms

nasdaq listing rule 5635(c)(4)

1 terms

nasdaq listing rule 5635(c)(4) regulatory

"The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4)..."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW HAVEN, Conn., April 06, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on April 1, 2026, Invivyd granted 16 newly hired non-executive employees options to purchase an aggregate of 1,083,750 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.

The options have a per share exercise price of $1.33, representing the closing price of Invivyd’s common stock on the grant date. Each option vests over four years, with 25% of the shares subject to such option vesting on the first anniversary of the employee’s start date and the remaining shares vesting in equal monthly installments thereafter, in each case, subject to the employee’s continuous service with Invivyd. The options have a 10-year term and are subject to the terms of the Invivyd, Inc. 2026 Inducement Plan.

About Invivyd  

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more. 

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

Contacts:

Media Relations
(781) 208-0160
media@invivyd.com

Investor Relations
(781) 208-1747
investors@invivyd.com

FAQ

How many option shares did Invivyd (IVVD) grant on April 1, 2026?

Invivyd granted a total of 1,083,750 option shares on April 1, 2026. According to the company, the grants were issued as inducements to 16 newly hired non-executive employees under its 2026 Inducement Plan.

What exercise price did Invivyd (IVVD) set for the April 1, 2026 inducement options?

The exercise price was set at $1.33 per share, equal to the closing price on April 1, 2026. According to the company, that price applies to all options granted under the inducement awards.

What is the vesting schedule for Invivyd (IVVD) inducement options granted April 1, 2026?

Each option vests over four years with 25% vesting after the first anniversary and monthly vesting thereafter. According to the company, vesting is subject to the employee’s continuous service with Invivyd.

How long do Invivyd (IVVD) inducement options remain exercisable?

The inducement options have a 10-year term from the grant date. According to the company, each option is subject to the terms of the Invivyd 2026 Inducement Plan and standard plan conditions.

Who received the inducement option grants from Invivyd (IVVD)?

The awards were granted to 16 newly hired non-executive employees as material inducements for employment. According to the company, the grants were made pursuant to Nasdaq Listing Rule 5635(c)(4).

Do the April 1, 2026 inducement options for Invivyd (IVVD) affect shareholder dilution?

Yes, the options represent potential dilution of 1,083,750 shares if exercised. According to the company, exercise and vesting conditions, plus plan terms, determine the eventual dilution and timing.